Uterus +Cervix+ 2 Falopian tube+2 Overy Biopsy - XL

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Diagnose benign or malignant diseases affecting female reproductive organs

₹899₹1,700

47% OFF

Uterus + Cervix + 2 Fallopian Tubes + 2 Ovaries Biopsy - XL

Why is it done?
- Detects malignant and benign neoplasms of the female reproductive organs including uterine cancer, cervical cancer, ovarian cancer, and fallopian tube malignancies
- Diagnoses chronic endometritis, polyps, fibroids, adenomyosis, and other uterine pathology
- Evaluates abnormal Pap smear results and cervical lesions for dysplasia or malignancy
- Assesses ovarian masses, cysts, and suspected ovarian pathology including endometriosis
- Investigates abnormal uterine bleeding, postmenopausal bleeding, and irregular menstrual patterns
- Evaluates infertility and recurrent pregnancy loss with suspected structural or histological abnormalities
- Confirms diagnosis of polycystic ovary syndrome (PCOS) and other endocrine disorders affecting reproductive organs
- Monitors response to hormonal or chemotherapy treatments in reproductive malignancies
Normal Range
- Normal Results: Benign, non-neoplastic histology consistent with normal reproductive organ architecture
- Negative/Normal Histology Indicators: No evidence of malignancy, dysplasia, or significant inflammation
- Uterus Normal: Intact endometrium without hyperplasia, adenomyosis, or neoplasia
- Cervix Normal: Intact squamous epithelium with normal maturation, no dysplasia (CIN 0), no HPV-related changes
- Fallopian Tubes Normal: Patent lumens with normal mucosal lining, no strictures, masses, or inflammatory changes
- Ovaries Normal: Normal follicular development without cysts, masses, or neoplasia; normal ovarian stroma
Interpretation
- Malignant Findings: Presence of adenocarcinoma, squamous cell carcinoma, sarcoma, or other malignant neoplasms; indicates cancer requiring immediate oncologic management
- Dysplasia/Precancerous Changes: CIN 1 (Mild dysplasia), CIN 2 (Moderate dysplasia), or CIN 3 (Severe dysplasia/carcinoma in situ); cervical intraepithelial neoplasia with increased cancer risk
- Endometrial Hyperplasia: Simple hyperplasia without atypia (low malignant risk) vs. complex atypical hyperplasia (high risk for endometrial cancer); atypical hyperplasia requires hysterectomy
- Chronic Endometritis: Presence of chronic inflammatory infiltrate suggesting infection or autoimmune response; associated with infertility and recurrent miscarriage
- Adenomyosis: Ectopic endometrial glands within myometrium; associated with dysmenorrhea, menorrhagia, and infertility
- Benign Tumors: Leiomyomas (fibroids), polyps, or benign cysts; generally have favorable prognosis but may require monitoring or surgical removal
- Ovarian Pathology: Mature cystic teratoma (dermoid cyst), mucinous/serous cystadenomas, or malignant epithelial ovarian tumors; determines surgical necessity and cancer risk
- Endometriosis: Presence of endometrial glands in ovarian tissue; associated with pelvic pain, infertility, and ovarian cyst formation
- HPV-Related Changes: Koilocytic changes indicating human papillomavirus infection; associated with increased cervical cancer risk, especially with high-risk HPV strains
Associated Organs
- Primary Organ Systems: Female reproductive system including uterus, cervix, fallopian tubes, and ovaries; closely associated with endocrine system (hormonal regulation) and pelvic lymphatic system
- Diseases Diagnosed or Monitored: Endometrial cancer, cervical cancer, ovarian cancer, fallopian tube cancer, uterine sarcoma, chronic pelvic inflammatory disease, tuberculosis of genital tract, infertility, recurrent miscarriage, and PCOS
- Medical Conditions Associated with Abnormal Results: Abnormal uterine bleeding, postmenopausal bleeding, dysmenorrhea, menorrhagia, pelvic pain, infertility, ectopic pregnancy risk, ovarian dysfunction, and estrogen-dependent neoplasia
- Potential Complications/Risks of Abnormal Findings: Metastatic cancer spread to lymph nodes, liver, lungs, and peritoneum; hemorrhage from malignant lesions; sepsis from untreated infection; peritonitis from ruptured cysts or tubal rupture; and organ failure in advanced disease
- Related Endocrine Associations: Estrogen and progesterone receptor status in tumors; impact on hormonal therapy response; metabolic syndrome in PCOS; and thyroid dysfunction association
Follow-up Tests
- For Malignancy: CT/MRI pelvis and abdomen, tumor markers (CA-125, CEA), immunohistochemistry for receptor status, molecular testing (MMR, MSI, BRCA mutations), and staging laparotomy or laparoscopy
- For Dysplasia/CIN: HPV testing, repeat Pap smear in 6-12 months, colposcopy with directed biopsies, and loop electrosurgical excision procedure (LEEP) or cold knife conization
- For Endometrial Hyperplasia: Hysteroscopy for visualization, repeat endometrial sampling in 3-6 months, hormone therapy (progestin), or hysterectomy for atypical hyperplasia
- For Chronic Endometritis: Antibiotic therapy, pelvic ultrasound, HSG (hysterosalpingography) for tubal patency, and infertility workup
- For Ovarian Masses: Tumor markers (CA-125, HE4, AFP, beta-hCG for germ cell tumors), pelvic MRI, CT staging, RIPE (Risk of Malignancy Index), and gynecologic oncology referral
- For Benign Pathology: Pelvic ultrasound follow-up, symptomatic management, hormonal therapy if indicated, and surgical intervention if needed
- For Infertility Cases: Hysterosalpingography, semen analysis, hormonal panel (FSH, LH, estradiol, progesterone), thrombophilia workup, and assisted reproductive technology evaluation
- Monitoring Frequency: Cancer surveillance every 3-4 months initially, then 6-12 months; dysplasia follow-up at 6-12 months; benign lesions assessed based on symptoms; ongoing pelvic imaging annually
Fasting Required?
- Fasting Required: No - Fasting is not required for tissue biopsies of reproductive organs
- Patient Preparation Requirements: Void bladder completely before procedure; schedule during follicular phase (first 10 days) of menstrual cycle when possible to avoid endometrial confusion
- Medications to Avoid: Discontinue anticoagulants (warfarin, dabigatran, apixaban) 5-7 days prior if possible (consult with physician); stop aspirin and NSAIDs 3 days before; avoid antiplatelet agents; continue essential cardiac medications
- Additional Preparation: Avoid douching, tampons, and sexual intercourse for 48 hours prior; use analgesia 30-60 minutes before procedure; sign informed consent acknowledging risks of infection, hemorrhage, and uterine perforation
- Contraindications: Active pregnancy (unless medically indicated), acute pelvic infection, uncontrolled bleeding disorder, and acute cervicitis; proceed with caution in patients with severe cervical stenosis

How our test process works!